BioNTech Management

Management criteria checks 4/4

BioNTech's CEO is Ugur Sahin, appointed in Jan 2008, has a tenure of 16.75 years. total yearly compensation is €3.06M, comprised of 22.9% salary and 77.1% bonuses, including company stock and options. directly owns 17.37% of the company’s shares, worth €4.46B. The average tenure of the management team and the board of directors is 4 years and 4.5 years respectively.

Key information

Ugur Sahin

Chief executive officer

€3.1m

Total compensation

CEO salary percentage22.9%
CEO tenure16.8yrs
CEO ownership17.4%
Management average tenure4yrs
Board average tenure4.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ugur Sahin's remuneration changed compared to BioNTech's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-€504m

Mar 31 2024n/an/a

€113m

Dec 31 2023€3m€700k

€930m

Sep 30 2023n/an/a

€3b

Jun 30 2023n/an/a

€4b

Mar 31 2023n/an/a

€6b

Dec 31 2022€6m€360k

€9b

Sep 30 2022n/an/a

€10b

Jun 30 2022n/an/a

€12b

Mar 31 2022n/an/a

€13b

Dec 31 2021€12m€360k

€10b

Sep 30 2021n/an/a

€7b

Jun 30 2021n/an/a

€4b

Mar 31 2021n/an/a

€1b

Dec 31 2020€17m€360k

€15m

Sep 30 2020n/an/a

-€410m

Jun 30 2020n/an/a

-€230m

Mar 31 2020n/an/a

-€192m

Dec 31 2019€7m€311k

-€179m

Sep 30 2019n/an/a

-€122m

Jun 30 2019n/an/a

-€116m

Mar 31 2019n/an/a

-€77m

Dec 31 2018€653k€210k

-€48m

Compensation vs Market: Ugur's total compensation ($USD3.37M) is below average for companies of similar size in the German market ($USD5.31M).

Compensation vs Earnings: Ugur's compensation has been consistent with company performance over the past year.


CEO

Ugur Sahin (59 yo)

16.8yrs

Tenure

€3,056,000

Compensation

Prof. Dr. Ugur Sahin, MD, is the Chief Executive Officer and Co-Founder of BioNTech SE since 2008 and serves as its Member of Management Board since 2008 and serves as its Chair of the Management Board. Pr...


Leadership Team

NamePositionTenureCompensationOwnership
Ugur Sahin
Co-Founder16.8yrs€3.06m17.37%
€ 4.5b
Ozlem Tureci
Co-Founder6.8yrs€814.00k0.38%
€ 98.5m
Jens Holstein
CFO & Member of Management Board3.3yrs€1.32m0.00068%
€ 174.4k
Sierk Poetting
MD, COO & Member of Management Board10.8yrs€821.00k0.32%
€ 81.4m
Ryan Richardson
Chief Strategy Officer4.8yrs€1.41m0.0062%
€ 1.6m
James Timothy Ryan
Chief Legal & Business Officer & Member of the Management Board1.1yrs€848.00kno data
Sean Marett
Executive Officerless than a year€133.00k0.34%
€ 88.0m
Zach Taylor
Senior Vice President of Corporate Development & Strategyless than a yearno datano data
Katalin Kariko
Senior VP & External Consultant for RNA Protein Replacement Therapiesno datano datano data
Oliver Henning
Senior Vice President of Operationsno datano datano data
Sebastian Kreiter
Senior Vice President of Immunotherapy & Preclinical Researchno datano datano data
Siegbert Kloos
Senior Vice President of Global R&D Digitalno datano datano data

4.0yrs

Average Tenure

57yo

Average Age

Experienced Management: 22UA's management team is considered experienced (4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Rudolf Staudigl
Supervisory Board Member2.3yrs€90.00k0.00017%
€ 43.6k
Ulrich Wandschneider
Independent Deputy Chairman Supervisory Board6.8yrs€114.00kno data
Michael Motschmann
Independent Supervisory Board Member16.8yrs€80.00kno data
Helmut Jeggle
Independent Supervisory Board Chairman16.8yrs€226.00k0.14%
€ 35.9m
Nicola Blackwood
Member of Supervisory Board1.4yrs€46.00kno data
Anja Morawietz
Supervisory Board Member2.3yrs€105.00k0.00010%
€ 25.7k

4.5yrs

Average Tenure

58.5yo

Average Age

Experienced Board: 22UA's board of directors are considered experienced (4.5 years average tenure).